Pepsin and Reflux Laboratory

Dr. Johnston's research laboratory aims to develop new treatments for reflux, which specifically target pepsin.
To contact Dr. Johnson, please email njohnston@mcw.edu.
Learn More about Dr. Johnston

Current and Future Translational Research: Oral Formulation

Human Subject Research
In Vitro Research
In Vivo Research

Human Subject Research

This research investigates the effects of oral Fosamprenavir for treatment of LPR in Humans.

Efficiency of Fosamprenavir Conversion by Established Human Laryngeal Epithelial Cell Cultures, in the Presence of Saliva and Sera, Measured by High-Performance Liquid Chromatography
, to Assess the Efficacy of Oral Fosamprenavir for Treatment of Laryngopharyngeal Reflux
Estimated Start Winter 2023

In Vitro Research

This research focuses on how amprenavir protects against Pepsin Mediated Laryngeal E-cadherin Cleavage and Matrix Metalloprotease Induction in vitro.

Topical Alginate Protection against Pepsin-Mediated Esophageal Damage: E-Cadherin Proteolysis and Matrix Metalloproteinase Induction.
The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.

In Vivo Research

This research explores the toxicology and outcomes relating to Fosamprenavir for treatment of LPR in animal models.

Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model

Current and Future Translational Research: Inhaled Formulation

Human Subject Research
In Vivo
In Vitro

Human Subject Research

Phase I, Randomized, Placebo Controlled, Dose Escalating Clinical Trial to Assess the Safety and Tolerability of Fosamprenavir via Dry Powder Inhaler in Healthy Volunteers
Estimated Start Spring 2024

In Vivo

This research explores the toxicology and outcomes relating to Fosamprenavir for treatment of LPR in animal models.

Toxicology of Inhaled Fosamprenavir as a Dry Powder for Laryngopharyngeal Reflux: Toxicology and Fluid Dynamics Modeling
Toxicity of inhaled Fosamprenavir, a dose finding animal model
o Currently working with KreaMedica, Quebec Canada, on this study

In Vitro

This research investigates the ideal particle size and deposition rate of Fosamprenavir particles for inhalation targeting the larynx via Dry Powder Inhaler

Computational Fluid Dynamic analysis of Inhaled Fosamprenavir

Research Timeline for Oral Suspension for LPR, Oral Suspension for GERD and Dry Powder Inhaler for LPR

Fosamprenavir Research | Pepsin and Reflux Lab

European Union of Phonetricians Congress Presentation 2023

Taiwan Voice Society Annual Meeting in conjunction with International Voice Symposium of TCVGH September 2022

Learn more about Dr. Johnston and her team's research accomplishments.聽

all

Grants Awards and Funding

Active Grants:

Title: Inhaled Fosamprenavir for the Treatment of Laryngopharyngeal Reflux (LPR)
Source: Falk Medical Trust Transformational Award
Category: Investigator Initiated Study
Dates: 11/30/2022 - 11/30/2023

Title: Investigation into the mechanisms by which topical alginates preserve esophageal epithelial barrier function during pepsin-acid insult.
Source: Reckitt Benckiser Health Limited
Category: Investigator Initiated Translational Research Grant
Dates: 01/01/23 鈥� 12/31/23

Title: Preparation for clinical trial of fosamprenavir
Source: N-Zyme Biomedical Inc.
Category: Industry Sponsored Grant
Dates: 01/01/2023 鈥� 31/12/2023

Research Interests

Extraesophageal reflux
Use of pepsin as a marker for extraesophageal reflux
Uptake of pepsin by laryngeal epithelial cells & its role in reflux - attributed laryngeal injury & disease
Isolate and identification of the receptor with which pepsin interacts on laryngeal epithelial cells
New therapeutics for reflux (pepsin inhibitors/receptor antagonists)
Role of reflux, specifically pepsin, in laryngopharyngeal cancers
Role of pepsin in Barrett鈥檚 esophagus and esophageal adenocarcinoma

Society Memberships

American Association for Cancer Research
Society for Bimolecular Sciences
Association for Research in Otolaryngology
American Broncho-Esophagological Association
果冻影院 Cancer Center
Clinical and Translational Science Institute of Southeast Wisconsin
OESO-Stanford SEMPIRE Multidisciplinary Platform of Esophagology
Membership of the World Organization for Specialized Studies on Diseases of the Esophagus (OESO) and our team are an OESO Stanford Esophageal Multidisciplinary Program in Innovative Research Excellence (OESO-SEMPIRE) Pilot Center of Excellence

Current Laboratory and Study Team Members

Nikki Johnston, PhD

Professor, Otolaryngology & Communication Sciences and Microbiology & Immunology

Jonathan Bock, MD

Professor

Joel H. Blumin, MD

Chief, Professor

Mark A. Vukovich, MSN, APNP

APP Outpatient

Tina Samuels, MS

Program Manager, Airway, Digestive, & Voice Research

Ally Lesnick

Research Coordinator

Simon Blaine-Sauer

Medical Student

Pelin Ergun, PhD

Postdoctoral Researcher

(Samuels TL, Aoun J, Husain I, Figueredo E, Richards D, Johnston N.) Ann N Y Acad Sci. 2024 Nov;1541(1):53-62 PMID: 39420555 SCOPUS ID: 2-s2.0-85206825163 10/18/2024
(Ergun P, Samuels TL, Mathison AJ, Plehhova K, Coyle C, Horvath L, Johnston N.) Int J Mol Sci. 2024 Oct 05;25(19) PMID: 39409043 PMCID: PMC11605242 SCOPUS ID: 2-s2.0-85206446606 10/16/2024
(Khampang P, Samuels TL, Blaine-Sauer S, Lucas J, Yan K, Johnston N, Kerschner JE.) Laryngoscope. 2024 Aug;134(8):3815-3819 PMID: 38401061 SCOPUS ID: 2-s2.0-85186458928 02/24/2024
(Lesnick A, Samuels TL, Seabloom D, Wuertz B, Ojha A, Seelig D, Ondrey F, Wiedmann TS, Hogan C, Torii E, Ouyang H, Yan K, Garcia GJM, Bock JM, Johnston N.) Laryngoscope Investig Otolaryngol. 2024 Feb;9(1):e1219 PMID: 38362183 PMCID: PMC10866582 02/16/2024
(Lesnick A, Samuels TL, Seabloom D, Wuertz B, Ojha A, Seelig D, Ondrey F, Wiedmann TS, Hogan C, Torii E, Ouyang H, Yan K, Garcia GJM, Bock JM, Johnston N.) Laryngoscope Investigative Otolaryngology. February 2024;9(1) SCOPUS ID: 2-s2.0-85183005384 02/01/2024

果冻影院